- Revenue Forecast: BioNTech has increased its full-year revenue forecast to between €2.60 billion and €2.80 billion, previously estimated between €1.70 billion and €2.20 billion.
- R&D Expenses: The company expects research and development expenses to range from €2.00 billion to €2.20 billion, improved from earlier predictions of €2.60 billion to €2.80 billion.
- SG&A Expenses: Selling, general, and administrative expenses are anticipated to be between €550 million and €650 million, revised down from previous estimates of €650 million to €750 million.
- Capital Expenditure: Forecasted capital expenditure is now set between €200 million and €250 million, a reduction from earlier forecasts of €250 million to €350 million.
- Third Quarter Performance: BioNTech reported a loss per share of €0.12, contrary to an expected loss per share of €0.96. The company previously had an EPS of €0.81 year-over-year.
- Quarterly Revenue: The company’s revenue for the third quarter was €1.52 billion, surpassing the estimate of €784.3 million.
- R&D Spending: Research and development expenses in the third quarter were €564.8 million, showing a year-over-year increase of 2.6%, though below the estimated €686.4 million.
- Operating Loss: An operating loss of €46.9 million was reported for the quarter, contrasting with a year-over-year profit of €10.5 million but better than the estimated loss of €359.7 million.
- Property and Equipment Purchases: Investments in property, plant, and equipment stood at €35.9 million, marking a significant 51% decrease from the previous year.
- Cash Reserves: Cash and cash equivalents increased by 4.9% year-over-year, amounting to €10.09 billion.
- Revenue Drivers: Increased revenues were mainly due to BioNTech’s collaboration with BMS recognized in Q3 of 2025, though partially offset by lower COVID-19 vaccine sales volumes.
BioNTech on Smartkarma
Independent analyst coverage of BioNTech on Smartkarma by Baptista Research sheds light on the company’s expansion beyond its successful COVID-19 vaccine. In their report titled “BioNTech SE: An Insight Into The BNT327 Combination Trials In Oncology,” Baptista Research highlights the significant progress BioNTech has made in oncology, showcasing a diversified strategy. While the company’s foray into oncology presents promising opportunities, Baptista Research cautions investors to carefully consider BioNTech’s financial performance and potential market uncertainties.
A look at BioNTech Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, BioNTech is poised for a positive long-term outlook. With high scores in Value, Momentum, and Resilience, the company shows strength in its market position, growth potential, and ability to navigate challenges. While the Dividend score is low, this is common for companies in the biotechnology sector focusing more on reinvesting profits into research and development rather than paying out dividends. BioNTech’s focus on developing innovative cancer treatments positions it well for continued growth and success in the biotechnological industry.
BioNTech, a company specializing in biotechnological solutions with a primary focus on developing treatments for cancer patients, has received favorable Smart Scores across key factors. These scores indicate a strong foundation in value, growth potential, market performance, and resilience to market fluctuations. With its global reach, BioNTech is well-positioned to continue making strides in the field of biotechnology and provide innovative solutions for cancer patients worldwide.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
